Incannex Healthcare (CHIA:IHL) - Stock Price, News & Analysis

IHL Stock Overview

IHL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 43.7% per year over past 5 years

Makes less than USD$1m in revenue (A$1M)

Does not have a meaningful market cap (A$65M)

Significant insider selling over the past 3 months

+ 3 more risks

Incannex Healthcare Inc. Competitors

PharmAust

ASX:PAA

AU$96.8m

Argenica Therapeutics

ASX:AGN

AU$66.3m

Vita Life Sciences

ASX:VLS

AU$122.6m

Arovella Therapeutics

ASX:ALA

AU$126.0m

Price History & Performance

Summary of all time highs, changes and price drops for Incannex Healthcare
Historical stock prices
Current Share Price	US$0.05
52 Week High	US$0.21
52 Week Low	US$0.044
Beta	2.09
1 Month Change	-25.37%
3 Month Change	-31.51%
1 Year Change	-75.31%
3 Year Change	-72.22%
5 Year Change	177.78%
Change since IPO	-38.27%

Recent updates

Shareholder Returns

	IHL	AU Pharmaceuticals	AU Market
7D	0%	-0.7%	-0.1%
1Y	-75.3%	31.6%	4.9%

Return vs Industry: IHL underperformed the Australian Pharmaceuticals industry which returned 10.2% over the past year.

Return vs Market: IHL underperformed the Australian Market which returned -0.5% over the past year.

Price Volatility

Is IHL's price volatile compared to industry and market?
IHL volatility
IHL Average Weekly Movement	13.4%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: IHL's share price has been volatile over the past 3 months.

Volatility Over Time: IHL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Joel Latham	www.incannex.com

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.

Incannex Healthcare Inc. Fundamentals Summary

How do Incannex Healthcare's earnings and revenue compare to its market cap?
IHL fundamental statistics
Market cap	AU$98.84m
Earnings (TTM)	-AU$19.98m
Revenue (TTM)	AU$1.01m

Over9,999x

P/S Ratio

-862.7x

P/E Ratio

Is IHL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IHL income statement (TTM)
Revenue	AU$1.01m
Cost of Revenue	AU$0
Gross Profit	AU$1.01m
Other Expenses	AU$20.99m
Earnings	-AU$19.98m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.013
Gross Margin	100.00%
Net Profit Margin	-1,970.61%
Debt/Equity Ratio	0%

How did IHL perform over the long term?

See historical performance and comparison

IHL Stock Overview

Rewards

Risk Analysis

Incannex Healthcare Inc. Competitors

ASX:PAA

AU$96.8m

ASX:AGN

AU$66.3m

ASX:VLS

AU$122.6m

ASX:ALA

AU$126.0m

Price History & Performance

Recent News & Updates

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Recent updates

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

New minor risk - Share price stability

New minor risk - Financial data availability

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

New minor risk - Market cap size

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Less than half of directors are independent

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.012 loss in FY 2021)

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)

Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program

Company Secretary Glenn Fowles has left the company

Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results

Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A

Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results

New 90-day high: AU$0.23

Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study

Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021

Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study

Incannex Healthcare Limited Receives Positive Results from Eurofins

Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan)

Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial

Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer

Full year earnings released - AU$0.0058 loss per share

An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million.

Shareholder Returns

Price Volatility

About the Company